384
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data*

, , , , , , , , & show all
Pages 256-258 | Received 13 Jan 2017, Accepted 19 Apr 2017, Published online: 02 Jun 2017
 

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1323270.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.